Jason Call, MD
Interventional Cardiology · Wailuku, HINPI 1528021862
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,822 of the $7,310 with a category attached, or 66.0%. 23 manufacturers reported payments, led by Endo Pharmaceuticals Inc. at 30.0% of the total. Reporting peaked in 2023 at $2,974 and has fallen 84.6% since, to $458 in 2025.
Across 145 payments — averaging $50.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endo Pharmaceuticals Inc.$2K
- Medtronic$2K
- Abiomed$878
- Edwards Lifesciences$380
- Abbott$352
- Shockwave Medical, Inc$347
- plus $1K from 17 others
Across 96 payments — averaging $2820.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$142K
- Novartis$49K
- Astrazeneca UK Limited$48K
- AstraZeneca$17K
- Amgen$8K
- Boston Scientific$5K
- plus $3K from 2 others
What the payments were for
- Consulting fees$1,04014%
- Travel & lodging$1,43420%
- Food & beverage$4,82266%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endo Pharmaceuticals Inc. | 6 | $2,193 |
| Medtronic(2 entities) | 52 | $1,812 |
| Abiomed | 9 | $878 |
| Edwards Lifesciences | 21 | $380 |
| Abbott | 6 | $352 |
| Shockwave Medical, Inc | 2 | $347 |
| Biotronik Inc. | 10 | $304 |
| Boston Scientific | 3 | $201 |
| Boehringer Ingelheim | 6 | $198 |
| Philips North America LLC | 5 | $137 |
| Celonova Biosciences, Inc. | 1 | $90 |
| Pfizer | 5 | $81 |
| E.r. Squibb & Sons, L.L.C. | 4 | $63 |
| Angiodynamics, Inc. | 2 | $58 |
| Bard Peripheral Vascular, Inc. | 2 | $46 |
| Lantheus Medical Imaging, Inc. | 2 | $35 |
| AstraZeneca | 2 | $35 |
| Novartis | 2 | $33 |
| Amgen | 1 | $18 |
| Penumbra, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $13 |
| Avinger Inc. | 1 | $11 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few interventional cardiology providers in Hawaiito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 132 | $148,711 |
| JardianceEmpagliflozin | 32 | $30,264 |
| XareltoRivaroxaban | 24 | $29,600 |
| EntrestoSacubitril/Valsartan | 11 | $17,629 |
| Metoprolol Succinate | 74 | $1,223 |
| Atorvastatin Calcium | 108 | $1,041 |
| ClopidogrelClopidogrel Bisulfate | 48 | $759 |
| Ezetimibe | 25 | $733 |
| Rosuvastatin Calcium | 53 | $729 |
| Losartan Potassium | 74 | $575 |
| Amlodipine Besylate | 83 | $537 |
| Guanfacine Hcl | 26 | $437 |
| Chlorthalidone | 29 | $353 |
| Amiodarone Hcl | 27 | $349 |
| Metoprolol Tartrate | 47 | $348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $81 | $148,711132 claims |
| Boehringer IngelheimJardiance | $198 | $30,26432 claims |
| Johnson & JohnsonXarelto | $13 | $29,60024 claims |
| NovartisEntresto | $33 | $17,62911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in Hawaiion file to place this against a meaningful peer group, so we don't.
Other interventional cardiology in Wailuku
- Colin LeeWailuku$610
- Joseph ChambersWailuku$437
- Steven FilardoWailuku$320
- John CoganHonolulu$82K
- Kris KawamotoHonolulu$25K
- Giselle Baquero CaranamaHonolulu$20K
- Atsushi TerakuboHonolulu$20K
- Kelly PaschkeHonolulu$7K
- John KaoHonolulu$6K
- John O'MaraHonolulu$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.